Gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients with advanced biliary tree cancers: A pilot study

Anticancer Research

Volumn 26, Issue 1 B, 2006, Pages 771-775

  Yamashita, Yo Ichi ^a,b   Taketomi, Akinobu ^a   Fukuzawa, Kengo ^b   Yoshizumi, Tomoharu ^a   Uchiyama, Hideaki ^a   Simada, Mitsuo ^c   Shirabe, Ken ^a   Wakasugi, Kenzo ^b   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b OITA RED CROSS HOSPITAL   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

5 Fluorouracil; Biliary tree cancers; Cisplatin; Gemcitabine

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLIC ACID; GEMCITABINE; INTERFERON; MITOMYCIN C; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE ACTIVITY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GALLBLADDER CARCINOMA; HUMAN; HUMAN TISSUE; LEUKOPENIA; MALE; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; CISPLATIN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; GALLBLADDER NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 32144458626     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Patel T: Increasing incidence and motality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33: 1353-1357, 2001.
2. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, Khan SA, Elliott P and Thomas HC: Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales. Gut 48: 816-820, 2001.
3. Davila JA and El Serag HB: Cholangiocarcinoma: the 'other' liver cancer on rise. Am J Gastroenterol 97: 3199-3200, 2002.
4. Gallardo JO, Rubio B, Fodor M, Orlandi L, Yanez M, Gamargo C and Ahumada M: A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 12: 1403-1406, 2001.
5. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, Depisch D, Krauss G, Schneeweiss B and Scheithauer W: Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 12: 183-186, 2001.
6. Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA and Tschetter LK: Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 103: 111-118, 2005.
7. Doval DC, Sekhon JS, Gupta SK, Fuloria J, Shukla VK, Gupta S and Awasthy BS: A phase II study of gemcitabine and CDDP in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 90: 1516-1520, 2004.
8. Patt YZ, Hassan MM, Lozano RD, Waugh KA, Hoque AM, Frome AI, Lahoti S, Ellis L, Vauthey JN, Curley SA, Schnirer II and Raijman I: Phase II trial of CDDP, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res 7: 3375-3380, 2001.
9. Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A and Louvet C: GERCOR Group. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15: 1339-1343, 2004.
10. Kuhn R, Hribaschek A, Eichelmann K, Rudolph S, Fahlke J and Ridwelski K: Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Invest New Drugs 20: 351-356, 2002.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors (RECIST) guidelines. J Natl Cancer Inst 92: 205-216, 2000.
12. Lin MH, Chen JS, Chen HH and Su WC: A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy 49: 154-158, 2003.
13. Kubicka S, Rudolph KL, Tietze MK, Lorenz M and Manns M: Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 48: 783-789, 2001.
14. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J and Moore MJ: Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23: 2332-2338, 2005.
15. Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez A, Reyes M, Mota A, Munoz D, Solorza G, Hinojosa LM, Guadarrama R, Florentino R, Mohar A, Melendez J, Maldonado V, Chanona J, Robles E and De la Garza J: A phase II study of gemcitabine and CDDP combination as induction chemotherapy for untreated locally advanced cervical carcinoma. Ann Oncol 12: 541-547, 2001.
16. Kornek GV, Schuell B, Laengle F, Gruenberger T, Penz M, Karall K, Depisch D, Lang F and Scheithauer W: Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol 15: 478-483, 2004.
17. Taieb J, Mitry E, Boige V, Artru P, Ezenfis J, Lecomte T, Clavero-Fabri MC, Vaillant JN, Rougier P and Ducreux M: Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin Ann Oncol 13: 1192-1196, 2002.
18. Raderer M, Hejna MH, Valencak JB, Kornek GV, Weinlander GS, Bareck E, Lenauer J, Brodowicz T, Lang F and Scheithauer W: Two consecutive phase II studies of 5-fluorouracil/ leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 56: 177-180, 1999.
19. Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, Kim JH, Lee JS and Kang YK: Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 14: 1115-1120, 2003.
20. Ren Q-F and Grem JL: Synergistic cytotoxity and induction of parental DNA fragmentation with sequential gemcitabine and 5-fluoro-2' deoxyuridine in HT29 colon cancer cells. National Cancer Institute-Navy Center, Bethesda, MD AACR, Vol 36: 2421, 1995.
21. van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ and Peters GJ: Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 80: 981-990, 1999.
22. van Moorsel CJ, Veerman G, Bergman AM, Guechev A, Vermorken JB, Postmus PE and Peters GJ: Combination chemotherapy studies with gemcitabine. Semin Oncol 24(2 Suppl 7): S7-17-S7-23, 1997.
23. Kondo S, Nimura Y, Hayakawa N, Kamiya J, Nagino M and Uesaka K: Extensive surgery for carcinoma of the gallbladder. Br J Surg 89: 179-184, 2002.